BLA 125277 · Dyax Corp.
Kalbitor
Ecallantide · Injection · Plasma Kallikrein Inhibitor
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 28, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Dec 1, 2009
Approved uses
2
Original approval plus efficacy supplements
Registered trials
12
4 Phase 3, 0 recruiting
FAERS reports
1,869
1,138 serious, 34 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ANAPHYLAXIS Anaphylaxis has been reported after administration of KALBITOR. Because of the risk of anaphylaxis, KALBITOR should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and hereditary angioedema. Healthcare professionals should be aware of the similarity of symptoms between hypersensitivity reactions and hereditary angioedema and patients should be monitored closely. Do not administer KALBITOR to patients with known clinical hypersensitivity to KALBITOR. [ see Contraindications (4) , Warnings and Precautions (5.1) , and Adverse Reactions (6) ] WARNING: ANAPHYLAXIS See full prescribing information for complete boxed warning Anaphylaxis has been reported after administration of KALBITOR ® . Because of the risk of anaphylaxis, KALBITOR should only be administered by a healthcare professional with appropriate medical...
What it is approved for
From the label in effect Jul 1, 2025.
KALBITOR ® (ecallantide) is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. KALBITOR is a plasma kallikrein inhibitor indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. ( 1 )
Mechanism: Hereditary angioedema (HAE) is a rare genetic disorder caused by mutations to C1-esterase-inhibitor (C1-INH) located on Chromosome 11q and inherited as an autosomal dominant trait. HAE is characterized by low levels of C1-INH activity and low levels of C4. C1-INH functions to regulate the activation of the complement and intrinsic coagulation (contact system pathway) and is a major endogenous inhibitor of plasma kallikrein. The kallikrein-kinin system is a complex proteolytic cascade involved in the initiation of both inflammatory and coagulation pathways. One critical aspect of this pathway...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 28, 2014 Supplement 70 · Efficacy · priority review LetterLabel
- Dec 1, 2009 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewSummary Review
1 products under this application
- KALBITOR · ECALLANTIDE 10MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ecallantide" as an intervention, any sponsor and status, largest first.
- A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss VolumePivotal-lookingCompleted
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT00816023 · 276 participants · Start Mar 2009 · Primary completion Dec 2009
Drug: ecallantide; placebo · For: Bloodloss; Surgical Procedures, Operative
Sites: Birmingham, Alabama; Montgomery, Alabama; Aurora, Colorado · 29 sites in all
- Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac SurgeryPivotal-lookingCompleted
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT00888940 · 243 participants · Start Jun 2009 · Primary completion Dec 2009
Drug: Ecallantide; Cyklokapron(R) · For: Bloodloss; Surgical Procedures, Operative
Sites: Birmingham, Alabama; Aachen, Germany; Augsburg, Germany · 34 sites in all
- Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT00456508 · 147 participants · Start Apr 1, 2007 · Primary completion Jun 1, 2010
Drug: ecallantide · For: Hereditary Angioedema (HAE)
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Berkeley, California · 41 sites in all
- Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT00457015 · 96 participants · Start Apr 1, 2007 · Primary completion Jun 1, 2008
Drug: ecallantide; Phosphate Buffer Saline (PBS), pH 7.0 · For: Hereditary Angioedema (HAE)
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Berkeley, California · 45 sites in all
- Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT00262080 · 91 participants · Start Dec 31, 2005 · Primary completion Dec 31, 2005
Drug: ecallantide; Phosphate Buffer Saline (PBS), · For: Hereditary Angioedema (HAE)
Sites: Wheaton, Maryland
ShireTakeda (TAK)
NCT01343823 · 79 participants · Start Jun 1, 2011 · Primary completion Jun 1, 2012
Drug: ecallantide 60 mg; ecallantide 30 mg and 4 more · For: ACE Inhibitor Induced Angioedema
Sites: Montgomery, Alabama; Colton, California; Los Angeles, California · 39 sites in all
ShireTakeda (TAK)
NCT01826916 · 77 participants · Start Nov 1, 2003 · Primary completion Dec 1, 2005
Drug: DX-88 (ecallantide) · For: Hereditary Angioedema (HAE)
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT00448864 · 75 participants · Start May 1, 2007 · Primary completion Jul 1, 2008
Drug: Ecallantide; Placebo · For: Blood Loss, Surgical
Sites: Birmingham, Alabama; Phoenix, Arizona; Aurora, Colorado · 15 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hereditary angioedema782
- off label use170
- drug ineffective147
- malaise86
- headache84
- product dose omission issue72
- pain70
- hypersensitivity68
- weight decreased68
- nausea67
- anaphylactic reaction62
- weight increased60
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 9 |
| 2011 | 20 |
| 2012 | 67 |
| 2013 | 70 |
| 2014 | 197 |
| 2015 | 333 |
| 2016 | 499 |
| 2017 | 69 |
| 2018 | 124 |
| 2019 | 86 |
| 2020 | 84 |
| 2021 | 78 |
| 2022 | 62 |
| 2023 | 38 |
| 2024 | 38 |
| 2025 | 64 |
| 2026 | 31 |
Recalls
1 FDA enforcement reports for this application.
Mar 17, 2017 · Class II · Terminated
Presence of Particulate Matter: Glass
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Kalbitor (Ecallantide)
2024 spending
$20.9M
Beneficiaries
36
284 claims
Per beneficiary
$579,766
$5,624.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $15,473,075 |
| 2021 | $20,767,296 |
| 2022 | $26,210,230 |
| 2023 | $24,976,935 |
| 2024 | $20,871,584 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of Treatment of Non-hereditary Angioedema.
van den Elzen M, Go MFCL, Knulst AC, et al. · Clin Rev Allergy Immunol 2018 · Systematic Review
- Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.
Sheffer AL, MacGinnitie AJ, Campion M, et al. · Ann Allergy Asthma Immunol 2013 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Ecallantide for the treatment of acute attacks in hereditary angioedema.
Cicardi M, Levy RJ, McNeil DL, et al. · N Engl J Med 2010 · Clinical Trial, Phase III, Multicenter Study
- Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department.
Bernstein JA, Moellman JJ, Collins SP, et al. · Ann Allergy Asthma Immunol 2015 · Clinical Trial, Phase II, Randomized Controlled Trial
- Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.
Lumry WR, Bernstein JA, Li HH, et al. · Allergy Asthma Proc 2013 · Clinical Trial, Research Support, Non-U.S. Gov't
- Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.
Sheffer AL, Campion M, Levy RJ, et al. · J Allergy Clin Immunol 2011 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Dyax Corp.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.